We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+0.37%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.56B
AUM Growth
-$92.1M
Cap. Flow
-$16.4M
Cap. Flow %
-1.05%
Top 10 Hldgs %
77.78%
Holding
44
New
2
Increased
8
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVNC
Revance Therapeutics, Inc.
RVNC
+$19.5M
2
EHTH icon
eHealth
EHTH
+$15.6M
3
SAGE
Sage Therapeutics
SAGE
+$6.86M
4
BIIB icon
Biogen
BIIB
+$6.02M
5
ALKS icon
Alkermes
ALKS
+$4.32M

Top Sells

Rank Stock Value
1
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$17.3M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$16.7M
3
ABMD
Abiomed Inc
ABMD
+$10.4M
4
AZN icon
AstraZeneca
AZN
+$10.1M
5
PBYI icon
Puma Biotechnology
PBYI
+$9.77M

Sector Composition

Rank Sector Weight
1 Healthcare 97.34%
2 Financials 2.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZGNX
26
DELISTED
Zogenix, Inc.
ZGNX
$2.99M 0.19%
183,800
-30,900
-14% -$453K
DNTH icon
27
Dianthus Therapeutics
DNTH
$6.29B
$1.92M 0.12%
27,019
– –
NVAX icon
28
Novavax
NVAX
$1.31B
$1.79M 0.11%
+12,500
New +$2.15M
RIGL icon
29
Rigel Pharmaceuticals
RIGL
$782M
$1.73M 0.11%
65,240
– –
AZN icon
30
AstraZeneca
AZN
$246B
$1.7M 0.11%
14,630
-86,115
-85% -$10.1M
MIRM icon
31
Mirum Pharmaceuticals
MIRM
$6.04B
$1.03M 0.07%
+64,700
New +$1.01M
ALIM
32
DELISTED
Alimera Sciences
ALIM
$1.03M 0.07%
200,919
– –
KLDO
33
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$815K 0.05%
341,030
-445,370
-57% -$1.81M
ALDX icon
34
Aldeyra Therapeutics
ALDX
$91.7M
$643K 0.04%
160,800
– –
TCMD icon
35
Tactile Systems Technology
TCMD
$555M
$516K 0.03%
27,100
– –
MRNS
36
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$372K 0.02%
31,330
– –
URGN icon
37
UroGen Pharma
URGN
$2.39B
$233K 0.01%
24,500
– –
NERV icon
38
Minerva Neurosciences
NERV
$187M
– –
-4,540
Closed -$63K
PBYI icon
39
Puma Biotechnology
PBYI
$459M
– –
-1,392,997
Closed -$9.77M
SYRS
40
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-8,060
Closed -$360K
VIRX
41
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-33,212
Closed -$266K
ACGN
42
DELISTED
Aceragen Inc
ACGN
– –
-4,537
Closed -$79K
ATNX
43
DELISTED
Athenex, Inc. Common Stock
ATNX
– –
-15,910
Closed -$958K
DRNA
44
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
– –
-855,713
Closed -$17.3M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q4 2021 Portfolio in Review

As of Q4 2021, Palo Alto Investors held 44 positions worth $1.56B, down 5.6% from $1.66B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Palo Alto Investors's Q4 2021 filing shows 2 new, 8 increased, 7 reduced and 7 closed positions. Its largest new stake was Novavax: 12,500 shares worth $1.79M. The largest sale was Dicerna Pharmaceuticals, Inc., an estimated $17.3M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q4 2021 buy was Novavax: 12,500 shares worth $1.79M.
  • Palo Alto Investors added most to Revance Therapeutics, Inc. in Q4 2021, an estimated $19.5M increase.
  • Palo Alto Investors's biggest Q4 2021 reduction was Vanda Pharmaceuticals, cutting an estimated $16.7M.
  • Palo Alto Investors fully exited Dicerna Pharmaceuticals, Inc. in Q4 2021, selling an estimated $17.3M.
  • Palo Alto Investors's ten largest holdings make up 78% of its $1.56B portfolio in Q4 2021.
  • Palo Alto Investors opened 2 new positions and closed 7 in Q4 2021.
  • Palo Alto Investors's portfolio value fell 5.6% quarter-over-quarter to $1.56B.

Based on Palo Alto Investors's 13F filing for Q4 2021, filed 14 Feb 2022.